



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant : David J. Grainger
Serial. No : 09/754,775 Examiner: Kim, Jennifer M.
Filed : January 4, 2001 Group Art Unit: 1617
For : PREVENTION AND TREATMENT OF CARDIOVASCULAR
PATHOLOGIES WITH TAMOXIFEN ANALOGUES


INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States
Postal Service as first class mail, in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450

February 13, 2006
Date of Deposit

Van H. Nguyen
Attorney Name


Signature

56,571
PTO Registration No.

February 13, 2006
Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of
the Examiner the documents listed infra and on the attached PTO 1449 and respectfully
requests that the listed documents be considered by the Examiner and made of record in the
above-captioned application.

- 1 Wärrri, Anni, Toremifene-Induced Regression in Breast Cancer, 1993, pp. 1-76 plus references I-V.
- 2 Wärrri, Anni and Harkonen, P., Indirect Regulation Of erbB2 Expression by Antiestrogen in Human Breast Cancer Cells, 1993, pp. 1-12.
- 3 Wärrri, Anni, Isola, Harkonen, Estrogen and antiestrogen regulation of amplified erbB2 gene expression and ectodomain shedding in BT-474 human breast cancer cells, 1993, pp. 1-24.
- 4 Wärrri, Anni et al., Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro, J Natl Cancer Inst. 1993 Sep 1;85(17):1412-8.
- 5 Sawada et al., Fifty-Two Week Oral Toxicity Study and Recovery Study of Toremifene Citrate (NK622) in Female Rats, 1992, Pharmacometrics [Oyo yakuri], Vol. 44, pp. 357-373. (with translation from Japanese pp. 1-16)
- 6 Wärrri AM, Laine AM, Majasuo KE, Alitalo KK, Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int J Cancer. 1991 Oct 21;49(4):616-23.
- 7 Vuorio T, Warri A, Sandberg M, Alitalo K, Vuorio E. Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors. Int J Cancer. 1988 Nov 15;42(5):774-9.

This Information Disclosure Statement is being filed in response to the office action mailed on August 11, 2005, and lists the full Wärrri thesis, attached references I-V of Wärrri, copies of the original and an English translation of the Sawada reference, of which the abstract of Wärrri and the Japanese language copy of Sawada were listed in the Examiner's form 892. Therefore, applicant does not believe that any fee is due in connection with the submission of this paper.

Copies of the listed documents are attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents


are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited document(s) do not constitute "prior art" under United States law, applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicant does not believe that any fee is required in connection with the submission of this document. However, should any fee be required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. Duplicate copies of this sheet are enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.

By: 
Lisa B. Kole
Patent Office Reg. No. 35,225

Van H. Nguyen
Patent Office Reg. No. 56,571

Attorneys for Applicants
BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, NY 10112-4498
(212) 408-2500

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 074973.0117	Serial No. 09/754,775
	Applicant David J. Grainger	
	Filing Date January 4, 2001	Group 1617
	Examiner Kim, Jennifer M.	



U.S. PATENT DOCUMENTS

*Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

FOREIGN PATENT DOCUMENTS

Exam Initial	No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	1	Wärri, Anni, Toremifene-Induced Regression in Breast Cancer, 1993, pp. 1-76 and references I-V.
	2	Wärri, Anni and Harkonen, P., Indirect Regulation Of erbB2 Expression by Antiestrogen in Human Breast Cancer Cells, 1993, pp. 1-12.
	3	Wärri, Anni, Isola, Harkonen, Estrogen and antiestrogen regulation of amplified erbB2 gene expression and ectodomain shedding in BT-474 human breast cancer cells, 1993, pp. 1-24.
	4	Wärri, Anni et al., Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro, J Natl Cancer Inst. 1993 Sep 1;85(17):1412-8.

NY02:540270.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 074973.0117	Serial No. 09/754,775
	Applicant David J. Grainger	
	Filing Date January 4, 2001	Group 1617
	Examiner Kim, Jennifer M.	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	5	Sawada et al., Fifty-Two Week Oral Toxicity Study and Recovery Study of Toremifene Citrate (NK622) in Female Rats, 1992, Pharmacometrics [Oyo yakuri], Vol. 44, pp. 357-373. (with translation from Japanese pp. 1-16)
	6	Wärri AM, Laine AM, Majasuo KE, Alitalo KK, Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int J Cancer. 1991 Oct 21;49(4):616-23.
	7	Vuorio T, Warri A, Sandberg M, Alitalo K, Vuorio E. Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors. Int J Cancer. 1988 Nov 15;42(5):774-9.

NY02:540270.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.